Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002252 · ClinicalTrials.gov registry record · NA
A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea
A NA study, sponsored by Sandoz.
- Completed
- Registry status
- NA
- Development phase
NCT00002252: Completed NA study, sponsored by Sandoz.
NCT00002252 is a NA study that has completed, run by Sandoz. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002252, a NA study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To determine the efficacy and safety of Sandostatin (octreotide) compared to placebo in controlling diarrhea which is a manifestation or complication of documented HIV infection and which is refractory (does not respond) to all known treatment classes.
Interventions
- DRUG Octreotide
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002252 record still lists
NCT00002252 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Octreotide is the first listed.
NCT00002252 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002252 about?
NCT00002252 is a clinical study titled "A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea". To determine the efficacy and safety of Sandostatin (octreotide) compared to placebo in controlling diarrhea which is a manifestation or complication of documented HIV infection and which is refractory (does not respond) to all known treatment classes.
What is the current status of trial NCT00002252?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002252?
The interventions under investigation include: Octreotide (DRUG).
Who is sponsoring clinical trial NCT00002252?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.